A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor–Positive, Human Epidermal Growth Factor 2 (HER2)–Negative Breast Cancer
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose This preliminary study was conducted to evaluate the association between Oncotype DX (ODX) recurrence score and traditional prognostic factors. We also developed a nomogram to predict subgroups with low ODX recurrence scores (less than 25) and to avoid additional chemotherapy treatments for those patients. Materials and Methods Clinicopathological and immunohistochemical variables were retrospectively retrieved and analyzed from a series of 485 T1-3N0-1miM0 hormone receptor–positive, human epidermal growth factor 2!negative breast cancer patients with available ODX test results at Asan Medical Center from 2010 to 2016. One hundred twenty-seven patients (26%) had positive axillary lymph node micrometastases, and 408 (84%) had ODX recurrence scores of ! 25. Logistic regression was performed to build a nomogram for predicting a low-risk subgroup of the ODX assay. Results Multivariate analysis revealed that estrogen receptor (ER) score, progesterone receptor (PR) score, histologic grade, lymphovascular invasion (LVI), and Ki-67 had a statistically significant association with the low-risk subgroup. With these variables, we developed a nomogram to predict the low-risk subgroup with ODX recurrence scores of ! 25. The area under the receiver operating characteristic curve was 0.90 (95% confidence interval [CI], 0.85 to 0.96). When applied to the validation group the nomogram was accurate with an area under the curve=0.88 (95% CI, 0.83 to 0.95). Conclusion The low ODX recurrence score subgroup can be predicted by a nomogram incorporating five traditional prognostic factors: ER, PR, histologic grade, LVI, and Ki-67. Our nomogram, which predicts a low-risk ODX recurrence score, will be a useful tool to help select patients who may or may not need additional ODX testing.
Abstract
Purpose This preliminary study was conducted to evaluate the association between Oncotype DX (ODX) recurrence score and traditional prognostic factors. We also developed a nomogram to predict subgroups with low ODX recurrence scores (less than 25) and to avoid additional chemotherapy treatments for those patients. Materials and Methods Clinicopathological and immunohistochemical variables were retrospectively retrieved and analyzed from a series of 485 T1-3N0-1miM0 hormone receptor–positive, human epidermal growth factor 2!negative breast cancer patients with available ODX test results at Asan Medical Center from 2010 to 2016. One hundred twenty-seven patients (26%) had positive axillary lymph node micrometastases, and 408 (84%) had ODX recurrence scores of ! 25. Logistic regression was performed to build a nomogram for predicting a low-risk subgroup of the ODX assay. Results Multivariate analysis revealed that estrogen receptor (ER) score, progesterone receptor (PR) score, histologic grade, lymphovascular invasion (LVI), and Ki-67 had a statistically significant association with the low-risk subgroup. With these variables, we developed a nomogram to predict the low-risk subgroup with ODX recurrence scores of ! 25. The area under the receiver operating characteristic curve was 0.90 (95% confidence interval [CI], 0.85 to 0.96). When applied to the validation group the nomogram was accurate with an area under the curve=0.88 (95% CI, 0.83 to 0.95). Conclusion The low ODX recurrence score subgroup can be predicted by a nomogram incorporating five traditional prognostic factors: ER, PR, histologic grade, LVI, and Ki-67. Our nomogram, which predicts a low-risk ODX recurrence score, will be a useful tool to help select patients who may or may not need additional ODX testing.
참고문헌 (31)
- Rosenberg J, "The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database", Breast Cancer Res Treat, 89, pp.47~54 (2005)
- Koscielny S, "Breast cancer : relationship between the size of the primary tumour and the probability of metastatic dissemination", Br J Cancer, 49, pp.709~715 (1984)
- Fisher B, "Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update", Cancer, 52, pp.1551~1557 (1983)
- Baak JP, "Proliferation is the strongest prognosticator in node-negative breast cancer : significance, error sources, alternatives and comparison with molecular prognostic markers", Breast Cancer Res Treat, 115, pp.241~254 (2009)
- Elston CW, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer:experience from a large study with long-term follow-up", Histopathology, 41, pp.154~161 (2002)
- Colditz GA, "Risk factors for breast cancer according to estrogen and progesterone receptor status", J Natl Cancer Inst, 96, pp.218~228 (2004)
- Joh JE, "The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists", Oncologist, 16, pp.1520~1526 (2011)
- Rouzier R, "Multigene assays and molecular markers in breast cancer : systematic review of health economic analyses", Breast Cancer Res Treat, 139, pp.621~637 (2013)
- Klein ME, "Prediction of the Oncotype DX recurrence score : use of pathology-generated equations derived by linear regression analysis", Mod Pathol, 26, pp.658~664 (2013)
- Kraus JA, "Semi-quantitative immunohistochemical assay versus oncotype DX((R))qRTPCR assay for estrogen and progesterone receptors : an independent quality assurance study", Mod Pathol, 25, pp.869~876 (2012)
- Fitzgibbons PL, "Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast", Arch Pathol Lab Med, 138, pp.595~601 (2014)
- Harris L, "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer", J Clin Oncol, 25, pp.5287~5312 (2007)
- Vataire AL, "Cost-effectiveness of a chemotherapy predictive test", Bull Cancer, 99, pp.907~914 (2012)
- Blohmer JU, "Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer : a cost-effectiveness evaluation in the German setting", J Med Econ, 16, pp.30~40 (2013)
- Orucevic A, "Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010to 2012 National Cancer Data Base analysis", Breast Cancer Res Treat, 157, pp.427~435 (2016)
- Albanell J, "Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer", Eur J Cancer, 66, pp.104~113 (2016)
- Carlson JJ, "The impact of the Oncotype Dx breast cancer assay in clinical practice : a systematic review and metaanalysis", Breast Cancer Res Treat, 141, pp.13~22 (2013)
- Clark BZ, "Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score : a quality assurance study of 1074 cases", Appl Immunohistochem Mol Morphol, 21, pp.287~291 (2013)
- Zbytek B, "Nottingham-defined mitotic score : comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score", Appl Immunohistochem Mol Morphol, 21, pp.48~53 (2013)
- Cuzick J, "Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer", J Clin Oncol, 29, pp.4273~4278 (2011)
- Chen LL, "The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death", Cancer, 115, pp.5071~5083 (2009)
- Orucevic A, "Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data", Breast Cancer Res Treat, 163, pp.51~61 (2017)
- Sparano JA, "Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer", N Engl J Med, 379, pp.111~121 (2018)
- Williams DJ, "Proliferation(Ki-67 and phosphohistone H3)and Oncotype DX recurrence score in estrogen receptor-positive breast cancer", Appl Immunohistochem Mol Morphol, 19, pp.431~436 (2011)
- Sahebjam S, "Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score", Br J Cancer, 105, pp.1342~1345 (2011)
- Tang P, "A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer", Cancer Invest, 28, pp.978~982 (2010)
- Auerbach J, "Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?", Arch Pathol Lab Med, 134, pp.1697~1701 (2010)
- Chaudhary LN, "Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score", Hematol Oncol Stem Cell Ther, 9, pp.48~54 (2016)
- Gage MM, "A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay", Clin Breast Cancer, 15, pp.467~472 (2015)
- Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
- Sparano JA, "Development of the 21-gene assay and its application in clinical practice and clinical trials", J Clin Oncol, 26, pp.721~728 (2008)